Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …

PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
被引用次数：114 相关文章

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …

PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - The Lancet Infectious …, 2021 - Elsevier
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
[HTML] thelancet.com

[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …

PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
[PDF] researchgate.net

[PDF][PDF] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …

PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - Lancet Infect …, 2021 - researchgate.net
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 …

PA Goepfert, B Fu, AL Chabanon… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a
baculovirus expression system being developed against SARS-CoV-2. We present interim …

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 …

PA Goepfert, B Fu, AL Chabanon… - The Lancet. Infectious …, 2021 - europepmc.org
Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a
baculovirus expression system being developed against SARS-CoV-2. We present interim …
[HTML] nih.gov

[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …

PA Goepfert, B Fu, AL Chabanon… - The Lancet. Infectious …, 2021 - ncbi.nlm.nih.gov
Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a
baculovirus expression system being developed against SARS-CoV-2. We present interim …
[HTML] sld.cu

[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …

PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - covid19.sld.cu
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
[PDF] binasss.sa.cr

[PDF][PDF] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …

PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - Lancet Infect …, 2021 - binasss.sa.cr
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 …

PA Goepfert, B Fu, AL Chabanon, MI Bonaparte… - 2021 - cabidigitallibrary.org
Abstract Background: CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …